Information Provided By: 
Fly News Breaks for September 26, 2018
ALXN
Sep 26, 2018 | 12:14 EDT
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Alexion Pharmaceuticals shares after the announced acquisition of Syntimmune. The analyst thinks investors will like additional evidence of deal execution from this management team, particularly following the Wilson acquisition earlier this year. He views the deal as "smart" and continues to like the setup for Alexion. Raymond keeps an Overweight rating on the name.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
